What is the official website of MSD Greece ?

The official website of MSD Greece is https://www.msd.gr/.

What is MSD Greece's cybersecurity risk score?

MSD Greece has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has MSD Greece experienced?

According to Rankiteo, MSD Greece currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has MSD Greece been affected by any supply chain cyber incidents ?

According to Rankiteo, MSD Greece has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does MSD Greece have SOC 2 Type 1 certification ?

According to Rankiteo, MSD Greece is not certified under SOC 2 Type 1.

Does MSD Greece have SOC 2 Type 2 certification ?

According to Rankiteo, MSD Greece does not hold a SOC 2 Type 2 certification.

Does MSD Greece comply with GDPR ?

According to Rankiteo, MSD Greece is not listed as GDPR compliant.

Does MSD Greece have PCI DSS certification ?

According to Rankiteo, MSD Greece does not currently maintain PCI DSS compliance.

Does MSD Greece comply with HIPAA ?

According to Rankiteo, MSD Greece is not compliant with HIPAA regulations.

Does MSD Greece have ISO 27001 certification ?

According to Rankiteo,MSD Greece is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does MSD Greece operate in ?

MSD Greece operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does MSD Greece have ?

MSD Greece employs approximately 141 people worldwide.

Does MSD Greece own any subsidiaries ?

MSD Greece presently has no subsidiaries across any sectors.

How many LinkedIn followers does MSD Greece have ?

MSD Greece's official LinkedIn profile has approximately 17,006 followers.

What is the NAICS classification code for MSD Greece ?

MSD Greece is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does MSD Greece have a Crunchbase profile ?

No, MSD Greece does not have a profile on Crunchbase.

Does MSD Greece have a LinkedIn profile ?

Yes, MSD Greece maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/msd-greece.

How many cybersecurity incidents has MSD Greece experienced ?

As of August 8, 2026, Rankiteo reports that MSD Greece has experienced 1 cybersecurity incidents.

How many peer or competitor companies does MSD Greece have ?

MSD Greece has an estimated 5,727 peer or competitor companies worldwide.

What types of cybersecurity incidents has MSD Greece faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

MSD Greece

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

MSD Greece Vendor Cyber Rating & Cyber Score

msd.gr

Add Your Compliance Badge

Επίσημος λογαριασμός LinkedIn της MSD Ελλάδας / Official LinkedIn handle for MSD Greece. Privacy policy: https://www.msdprivacy.com/gr/gr/ Terms of use: https://www.msd.gr/terms-of-use/ Στην MSD, πάντοτε ανακαλύπταμε και θα συνεχίσουμε να ανακαλύπτουμε θεραπείες έχοντας έναν και μόνο απώτερο σκοπό: να προσφέρουμε περισσότερη και καλύτερη ζωή σε όσο το δυνατόν περισσότερους ανθρώπους παγκοσμίως. Πρωτοπόρες θεραπείες για τον καρκίνο, τις καρδιοπάθειες, τον HIV, τον διαβήτη και τη φυματίωση είναι μερικές μόνο από τις ανακαλύψεις μας που έφεραν ελπίδα και βελτίωσαν τη ζωή των συνανθρώπων μας. Η MSD στις ΗΠΑ και τον Καναδά είναι γνωστή ως Merck & Co., Inc., Rahway, NJ, USA. Η MSD στην Ελλάδα Στην Ελλάδα, η MSD ξεκίνησε την λειτουργία της το

MSD Greece A.I CyberSecurity Scoring

Scoring History

MSD Greece

MSD Greece CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

MSD Greece

Breach

9/2025

MSD060270611182...

Loading…

A.I.

MSD Greece Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for MSD Greece

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD Greece in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for MSD Greece in 2026.

Incident Types MSD Greece vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD Greece in 2026.

Incident History - MSD Greece (X = Date, Y = Severity)

Loading…

SUBSIDIARY

MSD Greece Subsidiaries

MSD Greece

Pharmaceutical Manufacturing

Website: https://www.msd.gr/

Company Size: 201-500 employees

MSDPharmaceutical Manufacturing

MSD Saúde AnimalVeterinary Services

MSD Animal HealthPharmaceutical Manufacturing

MSD GCCPharmaceutical Manufacturing

MSD FrancePharmaceutical Manufacturing

MSD TürkiyePharmaceutical Manufacturing

MSD EspañaPharmaceutical Manufacturing

MSD EgyptPharmaceutical Manufacturing

MSD LATAMPharmaceutical Manufacturing

MSD PortugalPharmaceutical Manufacturing

MSD DeutschlandPharmaceutical Manufacturing

MSD ItaliaPharmaceutical Manufacturing

MSD NetherlandsPharmaceutical Manufacturing

MSD in the UKPharmaceutical Manufacturing

MSD SwitzerlandPharmaceutical Manufacturing

MSD Australia & New ZealandPharmaceutical Manufacturing

MSD RomaniaPharmaceutical Manufacturing

MSD Czech RepublicPharmaceutical Manufacturing

MSD PolskaPharmaceutical Manufacturing

MSD BelgiumPharmaceutical Manufacturing

MSD South AfricaPharmaceutical Manufacturing

MSD JordanPharmaceutical Manufacturing

MSD Animal Health UK LtdPharmaceutical Manufacturing

MSD Animal Health Technology LabsTechnology, Information and Internet

MSD ÖsterreichPharmaceutical Manufacturing

MSD FinlandPharmaceutical Manufacturing

MSD LebanonPharmaceutical Manufacturing

MSD NorgePharmaceutical Manufacturing

MSD SverigePharmaceutical Manufacturing

MSD MagyarországPharmaceutical Manufacturing

MSD SRBIJAPharmaceutical Manufacturing

MSD SlovenskoPharmaceutical Manufacturing

MSD DanmarkPharmaceutical Manufacturing

MSD UkrainePharmaceutical Manufacturing

Loading…

MSD Greece Similar Companies

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Loading…

NEWS

MSD Greece CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-52880

SUMMARY

Klever-Go is the Go implementation of the Klever blockchain protocol. Versions from 1.7.14 through 1.7.17 are vulnerable to a remotely triggerable denial of service. Both REST APIs are started with the Gin Engine.Run convenience method, which serves requests through Go's default HTTP server with no ReadHeaderTimeout, ReadTimeout, or MaxHeaderBytes configured. As a result, incoming connections that never complete their request headers are held open indefinitely. When a REST listener is reachable beyond localhost through the documented all-interface bind or a Docker port-publish deployment, a single unauthenticated client can open many slow-header connections and hold them open until server file descriptors are exhausted, preventing the API from accepting new connections. This renders the REST API unavailable to legitimate clients. This issue is fixed in version 1.7.18.

Published

Date2026-08-07

Updated

Date2026-08-07

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-52879

SUMMARY

Klever-Go is the Go implementation of the Klever blockchain protocol. In versions 1.7.14 through 1.7.17, the direct-message ingress handler spawns a new goroutine for every incoming direct message before the processor-level antiflood layer makes any admission decision, with no semaphore, throttler, or bound on the number of concurrent in-flight spawns. Because the antiflood check runs inside the spawned goroutine rather than before it, a single connected peer can open a direct-send stream and send a stream of well-formed messages to force unbounded goroutine creation, where each goroutine allocates its own stack and holds a message reference until processing completes, adding scheduler and garbage-collection pressure faster than the runtime can drain it. This lets one peer degrade the node's availability and its ability to process legitimate traffic, resulting in a remotely triggerable denial of service. The issue is fixed in 1.7.18.

Published

Date2026-08-07

Updated

Date2026-08-07

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-52878

SUMMARY

Klever-Go is the Go implementation of the Klever blockchain protocol. Versions 1.7.14 through 1.7.17 are vulnerable to a nil-pointer panic triggered by a protobuf Transaction whose embedded RawData sub-message is omitted. This omission causes RawData to decode to nil. Every transaction gossiped on the Klever-Go P2P network is decoded and validated synchronously inside the libp2p pubsub topic-validator callback, where txVersionChecker.CheckTxVersion dereferences tx.RawData.Version with no nil check. Because the libp2p pubsub callback, the underlying go-libp2p-pubsub validation worker, and Klever's own network/p2p layer install no recover(), the panic propagates and crashes the entire node process. The attacker payload is a 3-byte protobuf message; no validator key, stake, funds, or on-chain account is required, and delivery aimed at enough of the BLS validator set can halt block production, resulting in a chain halt. This issue has been fixed in version 1.7.18.

Published

Date2026-08-07

Updated

Date2026-08-07

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-49343

SUMMARY

Klever-Go is the Go implementation of the Klever blockchain protocol. In versions prior to 1.7.18, the account-data trie syncers are vulnerable to a resource-exhaustion flaw that leaks bounded throttler slots on error paths. In syncDataTrie() (in both userAccountsSyncer.go and kappAccountsSyncer.go), StartProcessing() reserves a slot from the NumGoRoutinesThrottler, but the corresponding EndProcessing() is only called on the success path and on the duplicate-root early return. As a result, any error from trie.NewTrie(), trie.NewTrieSyncer(), or trieSyncer.StartSyncing() (including the network-dependent timeout path) permanently consumes one slot for the lifetime of the throttler. An attacker who can repeatedly cause trie-node sync failures or timeouts during bootstrap can exhaust the bounded throttler, after which further account-data trie syncs stop making progress and SyncAccounts() returns a timeout. Because epoch bootstrap in syncUserAccountsState() and syncKappAccountsState() aborts on any such error, this causes bootstrap to fail, a core availability issue affecting fresh, restarting, or resyncing nodes and validators. This issue is fixed in version 1.7.18.

Published

Date2026-08-07

Updated

Date2026-08-07

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-48122

SUMMARY

Ruby LSP is an implementation of the language server protocol for Ruby. Several workspace-level settings in the Ruby LSP VS Code extension prior to version 0.10.4 could override the path to the Ruby executable, the version manager executables, or the Bundler `Gemfile` used at startup. A malicious repository containing a `.vscode/settings.json` could set these values to attacker-controlled targets. Opening and trusting the repository would then execute code with the privileges of the developer. The Ruby LSP gem and clients of the language server in other editors are not affected. Version 0.10.4 of the Ruby LSP VS Code extension fixes the issue.

Published

Date2026-08-07

Updated

Date2026-08-07

RISK INFORMATION (Score: )

cvss4

Base Score: 5.4

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:P/PR:L/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/Shopify/ruby-lsp/security/advisories/GHSA-2x7g-8mp4-572w

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…